Last update: May 14, 2021
Minimal risk for breastfeeding and infant.
Direct factor Xa inhibitor, indicated in the prevention of thromboembolism.
Administered orally every 12 to 24 hours.
Its pharmacokinetic data (large volume of distribution and high percentage of protein binding) explain the very small passage to milk observed in four different cases (Zhao 2020, Muysson 2019, Saito 2019, Wiesen 2016).
No problems were observed in an 18-month-old infant whose mother was treated with rivaroxaban from the first postpartum week (Saito 2019).
Several experts authors and expert consensus, consider the use of this medication to be safe or very probably safe during breastfeeding (LactMed, Hale, Daei 2021, Zhao 2020).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.